C4 Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, pioneering a new generation of medicines through targeted protein degradation. Using its Torpedo® platform, C4 designs small-molecule degraders that harness the body’s natural protein recycling system to selectively destroy disease-causing proteins. With several oncology programs in clinical trials and strategic partnerships with Roche, Biogen, Merck, and others, the company is translating this innovative approach into transformative therapies.